STAT+: Pharmalittle: We’re reading about a Viking obesity drug, Bausch Health’s bankruptcy denial, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Category: Pharmalot
STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates
CVS Caremark, one of the largest pharmacy benefit managers in the country, agreed to pay…
STAT+: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say
Amid concerns that the pharmaceutical industry abuses the U.S. patent system, a new paper suggests…
STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: A pricey Gilead HIV drug could be made for dramatically less than the company claims, researchers say
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a…
.jpg)
STAT+: Pharmalittle: We’re reading about Express Scripts overcharging postal workers, Gilead’s AIDS drug price, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: European Commission reaches deal with Vifor for ‘disparaging’ its only rival in iron deficiency market
Following a two-year probe, the European Commission has formalized a proposal from Vifor Pharma to…
STAT+: Express Scripts overcharged postal workers by $45 million, audit says
Express Scripts, one of the largest pharmacy benefit managers in the country, overcharged U.S. Postal…
STAT+: Pharmalittle: We’re reading about an FDA rare disease innovation hub, fewer U.S. drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down
A clutch of headlines last week suggested the U.S. Senate had achieved a breakthrough in…
STAT+: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: FTC plans to sue PBMs over the high cost of insulin and other medicines, reports say
The U.S. Federal Trade Commission reportedly plans to sue the three largest pharmacy benefit managers…
STAT+: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about an FTC report on PBMs, Lilly vs. Novo weight loss study, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: FTC report finds PBMs profit at the expense of patients and independent pharmacies
In stark terms, the Federal Trade Commission found in a report released Tuesday that pharmacy…
STAT+: South Africa and J&J reach a deal to widen access to a key tuberculosis treatment
South African antitrust authorities ended an investigation into Johnson & Johnson and its Janssen subsidiary…
STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Biden administration appeals jury finding in battle over patents for HIV prevention pills
The Biden administration has appealed a decision in which a federal court jury last year…
STAT+: U.K. trade group scolds Novo, Novartis, Pfizer and Otsuka for violating industry codes
Four large drugmakers — Novartis, Pfizer, Novo Nordisk, and Otsuka Pharmaceutical — were scolded by…
STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a GSK vaccine deal, an Alzheimer’s drug approval, and more
Top of the morning to you, and a fine one it is. The skies are…
STAT+: Pharmalittle: We’re reading about FTC probing Teva patents, a Moderna flu vaccine contract, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: After months of warnings, FTC opens investigation into Teva over ‘improper’ patents
The U.S. Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to…
STAT+: Pharmalittle: We’re reading about indicted drug wholesalers, a gene therapy rejection, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines
The owners of a drug wholesaler have been indicted for their alleged role in a…
STAT+: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Supreme Court rejects Purdue bankruptcy plan
The U.S. Supreme Court rejected a controversial bankruptcy deal in which the owners of Purdue…
STAT+: Pharmalittle: We’re reading about EMA plans for GLP-1 shortages, Walgreens store closings, and more
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Pharmalittle: We’re reading about rejection of an AbbVie Parkinson’s drug, PBM markups on mail order, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Novo’s Wegovy approval in China, a Merck KGaA cancer trial failure, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer
Pharmaceutical companies in the U.K. have increasingly violated a voluntary industry marketing code but complaints…
STAT+: Pharmalittle: We’re reading about a plan for Medicare coverage of Wegovy, an Alnylam heart drug, and more
Good morning, everyone, to another working week. We hope the weekend respite was relaxing and…
STAT+: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement…
STAT+: Doctors Without Borders is closing its widely regarded access-to-medicines campaign
In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has…
STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more
Rise and shine, everyone, another hot day is on the way. The forecast – at…
STAT+: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
.jpg)
STAT+: Pharmalittle: We’re reading about an ‘unaffordable’ Novartis drug, a new patent office rule, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Under pressure to thwart pharma patent abuse, the PTO proposes a new rule. But will it fly?
In a bid to prevent the patent system from being abused, the U.S. Patent and…
STAT+: Colorado state board decides a pricey Novartis medicine is unaffordable
A blockbuster arthritis drug from Novartis may face a limit on what Colorado health plans…
STAT+: Pharmalittle: We’re reading about abortion pill access, employer coverage of GLP-1 drugs and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Pfizer drug for Duchenne, bird flu vaccines for cows, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, an EU contract for bird flu vaccine, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed. We’re dealing…